Roche, Curis to study Erivedge in AML, MDS

|About: Roche Holding Ltd ADR (RHHBY)|By:, SA News Editor

Roche (RHHBY.OB) starts a Phase 1b/2 study of Erivedge — Curis' (CRIS) and Genentech's basal cell carcinoma treatment — in AML and MDS.

If abberant activation of the Hedgehog signaling pathway plays a role in AML development, then Erivedge (which is a Hedgehog pathway inhibitor) may be beneficial for AML and MDS patients.

CRIS COO Ali Fattaey is "extremely pleased with Roche's commitment to the continued development of Erivedge for treatment of patients with cancers where the Hedgehog pathway appears to be altered." (PR)